SEARCH

SEARCH BY CITATION

References

  • ART-LINC of IeDEA Study Group, Keiser O, Tweya H et al. (2009) Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS 23, 18671874.
  • Bartlett JA, DeMasi R, Quinn J, Moxham C & Rousseau F (2001) Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS 15, 13691377.
  • Braitstein P, Brinkhof MW, Dabis F et al. (2006) Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration; ART Cohort Collaboration (ART-CC) groups. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367, 817824.
  • Brennan AT, Maskew M, Sanne I & Fox MP (2010) The importance of clinic attendance in the first six months on antiretroviral treatment: a retrospective analysis at a large public sector HIV clinic in South Africa. Journal of the International AIDS Society 13, 49.
  • Brinkhof MW, Boulle A, Weigel R et al. (2009) Mortality of HIV-infected patients starting antiretroviral therapy in Sub-Saharan Africa: comparison with HIV-unrelated mortality. PLoS Medicine 6, e1000066. doi:10.1371/journal.pmed.1000066.
  • Chene G, Sterne JA, May M et al. (2003) Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 362, 679686. Epub 2003/09/06.
  • Cornell M, Grimsrud A, Fairall L et al. (2010) Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002–2007. AIDS 24, 22632270.
  • Deeks SG, Barbour JD, Martin JN, Swanson MS & Grant RM (2000) Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with HIV infection. Journal of Infectious Diseases 181, 946953.
  • Druyts E, Dybul M, Kanters S et al. (2013) Male sex and the risk of mortality among individuals enrolled in antiretroviral therapy programs in Africa: a systematic review and meta-analysis. AIDS 27, 417425.
  • Egger M, May M, Chene G et al. (2002) Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360, 119129.
  • Egger S, Petoumenos K, Kamarulzaman A et al. (2009) Long-term patterns in CD4 response are determined by an interaction between baseline CD4 cell count, viral load, and time: the Asia Pacific HIV observational database (APHOD). Journal of Acquired Immune Deficiency Syndromes 50, 513520.
  • Etard JF, Ndiaye I, Thierry-Mieg M et al. (2006) Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 20, 11811189.
  • Ferradini L, Jeannin A, Pinoges L et al. (2006) Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 367, 13351342.
  • Fox MP, Brennan A, Maskew M, MacPhail P & Sanne I (2010) Using vital registration data to update mortality among patients lost to follow-up from ART programmes: evidence from the Themba Lethu Clinic, South Africa. Tropical Medicine and International Health 15, 405413.
  • Fox MP, Maskew M, Macphail AP et al. (2012) Cohort profile: the Themba Lethu Clinical Cohort, Johannesburg, South Africa. International Journal of Epidemiology [Epub ahead of print]. Doi: 10.1093/ije/dys029.
  • Gange SJ, Mellors JW, Lau B et al. (2001) Longitudinal patterns of HIV type 1 RNA among individuals with late disease progression. AIDS Research and Human Retroviruses 17, 12231229.
  • Keiser O, Orrell C, Egger M et al. (2008) Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. PLoS Medicine 5, e148.
  • Lanoy E, May M, Mocroft A et al. (2009) Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. AIDS 23, 21992208.
  • Lawn SD, Myer L, Orrell C, Bekker LG & Wood R (2005) Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS 19, 21412148.
  • Lawn SD, Myer L, Harling G et al. (2006a) Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clinical Infectious Diseases 43, 770776.
  • Lawn SD, Myer L, Bekker LG & Wood R (2006b) Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 20, 16051612.
  • Lawn SD, Harries AD, Anglaret X, Myer L & Wood R (2008) Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 22, 18971908.
  • Lawn SD, Little F, Bekker LG et al. (2009) Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS 23, 335342.
  • Ledergerber B, Egger M, Opravil M et al. (1999) Clinical progression and virologic failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 353, 863868.
  • Lima VD, Fink V, Yip B et al. (2009) Association between HIV-1 RNA level and CD4 cell count among untreated HIV-infected individuals. American Journal of Public Health 99, S193S196.
  • May M, Boulle A, Phiri S et al. (2010) Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet 376, 449457.
  • Miller V, Staszewski S, Nisius G et al. (1999) Risk of new AIDS diseases in people on triple therapy. Lancet 353, 463.
  • Mocroft A, Ledergerber B, Katlama C et al. (2003) Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 362, 2229.
  • Moh R, Danel C, Messou E et al. (2007) Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. AIDS 21, 24832491.
  • National Department of Health, Republic of South Africa (2004) National Antiretroviral Treatment Guidelines Jacana Publishers, Johannesburg, South Africa.
  • National Department of Health, Republic of South Africa (2010) The South African Antiretroviral Treatment Guidelines. http://www.doh.gov.za/docs/factsheets/guidelines/art.pdf.
  • Pérez-Hoyos S, del Amo J, Muga R et al. (2003) Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: differences by transmission category. AIDS 17, 353359.
  • Phillips AN, Lampe FC, Smith CJ et al. (2010) Ongoing changes in HIV RNA levels during untreated HIV infection: implications for CD4 cell count depletion. AIDS 24, 15611567.
  • Rosen S & Fox MP (2011) Retention in HIV care between testing and treatment in Sub-Saharan Africa: a systematic review. PLoS Medicine 8.
  • Rothman KJ & Greenland S (eds.) (1998). Modern Epidemiology. Lippincott Williams & Wilkins, Philadelphia, PA.
  • Rubin DB (1987). Multiple Imputation for Nonresponse in Surveys. John Wiley & Sons, New York.
  • SAS. The MI Procedure. http://support.sas.com/rnd/app/papers/miv802.pdf.
  • SAS. The MIANALYZE Procedure. http://support.sas.com/rnd/app/papers/mianalyzev802.pdf.
  • Sethi A, Celentano D, Gange S, Moore R & Gallant J (2003) Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clinical Infectious Diseases 37, 11121118.
  • Smith CJ, Sabin CA, Youle MS et al. (2004) Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy. Journal of Infectious Diseases 190, 18601868.
  • Statistics South Africa (2005) Mortality and causes of death in South Africa, 1997-2003. Findings from death notification. P0309.3.
  • Sterne JA, Hernán MA, Ledergerber B et al. (2005) Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 366, 378384.
  • Stringer JS, Zulu I, Levy J et al. (2006) Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 296, 782793.
  • The Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord, Young J, Psichogiou M et al. (2012) CD4 Cell Count and the risk of AIDS or death in HIV-infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE. PLoS Medicine 9, e1001194. doi: 10.1371/journal.pmed.1001194.
  • Timaeus I, Dorrington R, Bradshaw D & Nannan N (2002). Mortality Trends in South Africa 1985–2000: From Apartheid to AIDS. South African Medical Research Council, Cape Town.
  • van Sighem AI, van de Wiel MA, Ghani AC et al. (2003) Mortality and progression to AIDS after starting highly active antiretroviral therapy. AIDS 17, 22272236.
  • Viard JP, Mocroft A, Chiesi A et al. (2001) Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. Journal of Infectious Diseases 183, 12901294.
  • World Health Organization (2007) Management of HIV Infection and Antiretroviral Therapy in Adults and Adolescents. A Clinical Manual. http://www.searo.who.int/LinkFiles/ Publications_Management_HIV_infection_antiretroviral_therapy_adults_adolescents.pdf. Accessed 8 April 2008.
  • Zachariah R, Fitzgerald M, Massaquoi M et al. (2006) Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. AIDS 20, 23552360.
  • Zou G (2004) A modified poisson regression approach to prospective studies with binary data. American Journal of Epidemiology 159, 702706.